Quantification of immunoblot results did reveal an induction of EpCAM expression levels in Du145 cells treated with 1.8 and 18 nM EGF and RL95-2 endometrial carcinoma cells with 9 nM EGF for 72 hr, and a slight reduction of EpCAM expression following 1.8 and 18 nM EGF treatment of Cal33 (Fig 2J, S4D and S4E Fig). The gene discussed is EGF; the disease is endometrial carcinoma.